MedTrace Logo

Fresolimumab In Systemic Sclerosis

NCT01284322 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-07-16

No results posted yet for this study

Summary

The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.

Conditions

  • Diffuse Systemic Sclerosis

Interventions

DRUG

Fresolimumab

intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients

Sponsors & Collaborators

  • Boston University

    lead OTHER

Principal Investigators

  • Robert Lafyatis, MD · Boston University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-06-30
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284322 on ClinicalTrials.gov